Celyad Oncology SA

Equities

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 12:35:07 2024-03-28 pm EDT 5-day change 1st Jan Change
0.351 EUR -1.13% Intraday chart for Celyad Oncology SA -2.50% -10.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC MT
Celyad Oncology CEO Resigns MT
Celyad Oncology CEO Steps Down for Personal Reasons MT
Celyad Oncology SA Announces Executive Change CI
Celyad Oncology Sa Announces Executive Change CI
Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A. CI
Celyad Oncology to Cancel American Depository Receipt Program in October MT
Transcript : Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023
Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Celyad Oncology Secures EUR10 Million via Private Placement With Historical Investors MT
Celyad Oncology SA announced that it expects to receive ?9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors CI
Celyad Oncology SA(OTCUS:CYAD.Y) dropped from NASDAQ Composite Index CI
Celyad Oncology's American Depositary Shares to Be Delisted from Nasdaq MT
Celyad Oncology Receives Delisting Notice From Nasdaq MT
Forecast-Beating Apple Results Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
Belgium's Celyad Oncology to Delist ASDs from Nasdaq MT
Celyad Oncology to Delist From Nasdaq Global Market MT
Celyad Oncology in Breach of Nasdaq's Listing Rule MT
Transcript : Celyad Oncology SA, 2022 Earnings Call, Mar 24, 2023
Celyad Oncology SA Appoints Georges Rawadi as its New Chief Executive Officer CI
Celyad Oncology Names Georges Rawadi as Chief Executive MT
Celyad Oncology Appoints New CEO MT
Celyad Oncology SA Auditor Raises 'Going Concern' Doubt CI
Sector Update: Health Care Stocks' Late Recovery Stalls MT
Sector Update: Health Care Stocks Moderately Lower MT
Chart Celyad Oncology SA
More charts
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Celyad Oncology SA - Euronext Bruxelles
  4. News Celyad Oncology SA
  5. Celyad Oncology : JonesTrading Downgrades Celyad Oncology to Hold from Buy